Matches in SemOpenAlex for { <https://semopenalex.org/work/W2484540610> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2484540610 abstract "Background: We previously reported about immune suppression in breast cancer patients at this meeting. In brief, tumor tissue specimens and peripheral blood mononuclear cells (PBMC) were analyzed in 50 early or advanced breast cancer (BC) patients. To compare between 38 early and 12 advanced BC cases, CD163-positive tumor cells and CCR4-positive tumor cells were detected more frequently in advanced cases than in early cases. Regulatory T (Treg) cells in PBMC significantly increased in percentage of the population in 37 BC patients than in 21 healthy volunteers (AACR 2011). In addition, several cytokines were examined in that cohort and plasma IL-17A had significantly higher levels in early BC than in advanced BC (AACR 2013). Then, we examined their prognosis and immunological profile. Patients and methods: Treg cells were examined by counting CD4+CD25highCD127low/-cells in PBMC with flow cytometry analysis. Immunohistochemical evaluation of tumor specimens was performed with monoclonal antibodies of HLA-ABC and DR, CD56, CD68, CD83, CD163 and CCR4. The number of stained cells was analyzed using a semiquantitative ordinal scale ranging from 0 to 3 (0, +/-, ++, +++). Human IL-2, IL-4, IL-6, IL-10, TNF, INFγ and IL-17A were measured using cytometric beads array system. Most patients received chemotherapy, hormonal therapy, and/or anti-HER2 therapy on the basis of intrinsic subtype and breast irradiation after breast-conserving surgery. Results and discussions: At the median follow-up of 7 years after blood sample collection, only 2 operable patients relapsed and 3 patients including 2 cases of stage IV died of disease. Of 5 cases of stage IV or recurrent BC, CD163 and/or CCR4 were strongly stained positive in tumor cells. There were significant differences of staining intensity in CD163 and CCR4-positive tumor cells between those cases and the rest 45 cases (p Conclusion: Targeted therapy against M2 macrophage or CCR4 is considered as a promising strategy of advanced breast cancer. Citation Format: Shigeru Imoto, Takayuki Ueno, Hirotsugu Isaka, Hiroki Ito, Kaisuke Miyamoto, Tomohiro Chiba, Hiroshi Kamma. Immunological profile of metastatic or recurrent breast cancer patients. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4138." @default.
- W2484540610 created "2016-08-23" @default.
- W2484540610 creator A5015330532 @default.
- W2484540610 creator A5035092212 @default.
- W2484540610 creator A5037426292 @default.
- W2484540610 creator A5053575826 @default.
- W2484540610 creator A5061220478 @default.
- W2484540610 creator A5066129979 @default.
- W2484540610 creator A5073794509 @default.
- W2484540610 date "2016-07-15" @default.
- W2484540610 modified "2023-09-26" @default.
- W2484540610 title "Abstract 4138: Immunological profile of metastatic or recurrent breast cancer patients" @default.
- W2484540610 doi "https://doi.org/10.1158/1538-7445.am2016-4138" @default.
- W2484540610 hasPublicationYear "2016" @default.
- W2484540610 type Work @default.
- W2484540610 sameAs 2484540610 @default.
- W2484540610 citedByCount "0" @default.
- W2484540610 crossrefType "proceedings-article" @default.
- W2484540610 hasAuthorship W2484540610A5015330532 @default.
- W2484540610 hasAuthorship W2484540610A5035092212 @default.
- W2484540610 hasAuthorship W2484540610A5037426292 @default.
- W2484540610 hasAuthorship W2484540610A5053575826 @default.
- W2484540610 hasAuthorship W2484540610A5061220478 @default.
- W2484540610 hasAuthorship W2484540610A5066129979 @default.
- W2484540610 hasAuthorship W2484540610A5073794509 @default.
- W2484540610 hasConcept C121608353 @default.
- W2484540610 hasConcept C126322002 @default.
- W2484540610 hasConcept C137061746 @default.
- W2484540610 hasConcept C142724271 @default.
- W2484540610 hasConcept C143998085 @default.
- W2484540610 hasConcept C159654299 @default.
- W2484540610 hasConcept C185592680 @default.
- W2484540610 hasConcept C202751555 @default.
- W2484540610 hasConcept C203014093 @default.
- W2484540610 hasConcept C204232928 @default.
- W2484540610 hasConcept C2775858924 @default.
- W2484540610 hasConcept C2776460901 @default.
- W2484540610 hasConcept C2779244956 @default.
- W2484540610 hasConcept C2908647359 @default.
- W2484540610 hasConcept C530470458 @default.
- W2484540610 hasConcept C55493867 @default.
- W2484540610 hasConcept C71924100 @default.
- W2484540610 hasConcept C8891405 @default.
- W2484540610 hasConcept C90924648 @default.
- W2484540610 hasConcept C99454951 @default.
- W2484540610 hasConceptScore W2484540610C121608353 @default.
- W2484540610 hasConceptScore W2484540610C126322002 @default.
- W2484540610 hasConceptScore W2484540610C137061746 @default.
- W2484540610 hasConceptScore W2484540610C142724271 @default.
- W2484540610 hasConceptScore W2484540610C143998085 @default.
- W2484540610 hasConceptScore W2484540610C159654299 @default.
- W2484540610 hasConceptScore W2484540610C185592680 @default.
- W2484540610 hasConceptScore W2484540610C202751555 @default.
- W2484540610 hasConceptScore W2484540610C203014093 @default.
- W2484540610 hasConceptScore W2484540610C204232928 @default.
- W2484540610 hasConceptScore W2484540610C2775858924 @default.
- W2484540610 hasConceptScore W2484540610C2776460901 @default.
- W2484540610 hasConceptScore W2484540610C2779244956 @default.
- W2484540610 hasConceptScore W2484540610C2908647359 @default.
- W2484540610 hasConceptScore W2484540610C530470458 @default.
- W2484540610 hasConceptScore W2484540610C55493867 @default.
- W2484540610 hasConceptScore W2484540610C71924100 @default.
- W2484540610 hasConceptScore W2484540610C8891405 @default.
- W2484540610 hasConceptScore W2484540610C90924648 @default.
- W2484540610 hasConceptScore W2484540610C99454951 @default.
- W2484540610 hasLocation W24845406101 @default.
- W2484540610 hasOpenAccess W2484540610 @default.
- W2484540610 hasPrimaryLocation W24845406101 @default.
- W2484540610 hasRelatedWork W1964363300 @default.
- W2484540610 hasRelatedWork W1985273729 @default.
- W2484540610 hasRelatedWork W2010323184 @default.
- W2484540610 hasRelatedWork W2316570776 @default.
- W2484540610 hasRelatedWork W2349344521 @default.
- W2484540610 hasRelatedWork W2353674681 @default.
- W2484540610 hasRelatedWork W2365008155 @default.
- W2484540610 hasRelatedWork W2416647441 @default.
- W2484540610 hasRelatedWork W2476007912 @default.
- W2484540610 hasRelatedWork W2600605934 @default.
- W2484540610 hasRelatedWork W2611033623 @default.
- W2484540610 hasRelatedWork W2802109771 @default.
- W2484540610 hasRelatedWork W2896640751 @default.
- W2484540610 hasRelatedWork W3005080811 @default.
- W2484540610 hasRelatedWork W3007479180 @default.
- W2484540610 hasRelatedWork W3161676085 @default.
- W2484540610 hasRelatedWork W3178166868 @default.
- W2484540610 hasRelatedWork W3181512247 @default.
- W2484540610 hasRelatedWork W3184953931 @default.
- W2484540610 hasRelatedWork W870358426 @default.
- W2484540610 isParatext "false" @default.
- W2484540610 isRetracted "false" @default.
- W2484540610 magId "2484540610" @default.
- W2484540610 workType "article" @default.